1. Home
  2. NSPR vs ALGS Comparison

NSPR vs ALGS Comparison

Compare NSPR & ALGS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo InspireMD Inc.

NSPR

InspireMD Inc.

HOLD

Current Price

$0.72

Market Cap

33.7M

Sector

Health Care

ML Signal

HOLD

Logo Aligos Therapeutics Inc.

ALGS

Aligos Therapeutics Inc.

HOLD

Current Price

$5.55

Market Cap

34.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
NSPR
ALGS
Founded
2005
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Medical/Dental Instruments
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
33.7M
34.6M
IPO Year
2009
2020

Fundamental Metrics

Financial Performance
Metric
NSPR
ALGS
Price
$0.72
$5.55
Analyst Decision
Buy
Strong Buy
Analyst Count
1
3
Target Price
$4.00
$39.33
AVG Volume (30 Days)
39.9K
112.6K
Earning Date
05-04-2026
05-05-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
88.30
EPS
N/A
N/A
Revenue
$2,310,000.00
$2,186,000.00
Revenue This Year
$57.98
$32.20
Revenue Next Year
$95.41
$4.71
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.63
$3.98
52 Week High
$2.59
$13.69

Technical Indicators

Market Signals
Indicator
NSPR
ALGS
Relative Strength Index (RSI) 51.86 56.92
Support Level $0.69 $4.80
Resistance Level $0.72 $5.94
Average True Range (ATR) 0.03 0.50
MACD 0.01 0.06
Stochastic Oscillator 89.14 84.07

Price Performance

Historical Comparison
NSPR
ALGS

About NSPR InspireMD Inc.

InspireMD Inc is a United States-based medical device company. It is focused on the development and commercialization of proprietary MicroNet stent platform technology for the treatment of complex vascular and coronary disease. The products of the company are the CGuard carotid Embolic Prevention System (CGuard EPS) and the MGuard Prime Embolic Protection System. It generates the majority of the revenue from the sales of CGuard EPS, which combines MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. The Company has one operating and reporting segment that develops, manufactures, and markets products for the treatment of carotid artery disease and other vascular diseases, including the Company's proprietary CGuard stent platform.

About ALGS Aligos Therapeutics Inc.

Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.

Share on Social Networks: